Cetuximab and Chemoradiation Therapy Significantly Improves Overall Survival of Patients with Unresectable Stage III NSCLC

Non-small cell lung cancers (NSCLC) commonly express the epidermal growth factor receptor (EGFR), which is associated with poor clinical outcome. Cetuximab is an inhibitor of EGFR and has radio-sensitization properties. In this study of patients with unresectable Stage III NSCLC, combining cetuximab  with paclitaxel, carboplatin and radiation therapy resulted in a median survival of 22.7 mths and a 2yr overall survival of 49.3% (double that of standard treatment). I like this approach because it provides further proof of the benefits that can be achieved when molecular stratification of patients is performed prior to therapy.
Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Non–Small-Cell Lung Cancer: RTOG 0324.

Speak Your Mind